RecruitingPhase 2NCT06863402

Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype

Nemtabrutinib and Pembrolizumab in Patients With Richter Transformation: A Phase II Study

Sponsor

Roswell Park Cancer Institute

Enrollment

32 participants

Start Date

Apr 15, 2026

Study Type

INTERVENTIONAL

Conditions

Richter Syndrome

Summary

This phase II trial tests how well nemtabrutinib in combination with pembrolizumab works in treating patients with Richter transformation, diffuse large B-cell lymphoma subtype (RT-DLBCL). Nemtabrutinib is in a class of medications called kinase inhibitors. It blocks a protein called BTK, which is present on B-cells (a type of white blood cell) in cancers such as Richter transformation at abnormal levels. This may help keep cancer cells from growing and spreading. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread. Giving nemtabrutinib in combination with pembrolizumab may kill more cancer cells in patients with RT-DLBCL.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing two drugs — nemtabrutinib and pembrolizumab (an immunotherapy) — for people with Richter transformation, a condition where chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) transforms into an aggressive large B-cell lymphoma. **You may be eligible if...** - You have a confirmed diagnosis of Richter transformation into diffuse large B-cell lymphoma (DLBCL) arising from CLL or SLL - You are either ineligible for standard chemotherapy (like R-CHOP), or your cancer has progressed after prior treatment for Richter transformation - Any side effects from prior therapies have recovered to mild or baseline levels **You may NOT be eligible if...** - Your lymphoma transformation is not the DLBCL subtype of Richter transformation - You have active serious infections or immune-related conditions that are uncontrolled - You have significant residual side effects from prior treatments Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREBiospecimen Collection

Undergo blood sample collection

PROCEDUREBone Marrow Biopsy

Undergo bone marrow biopsy

PROCEDUREComputed Tomography

Undergo PET/CT or CT

PROCEDUREEchocardiography

Undergo ECHO

PROCEDUREMultigated Acquisition Scan

Undergo MUGA

DRUGNemtabrutinib

Given PO

BIOLOGICALPembrolizumab

Given IV

PROCEDUREPositron Emission Tomography

Undergo PET/CT

OTHERQuestionnaire Administration

Ancillary studies

Locations(1)

Roswell Park Cancer Institute

Buffalo, New York, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06863402

Related Trials

Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma

NCT044913701 location

Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT053880063 locations

Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation

NCT056721732 locations

Evaluation of Treatment by Glofitamab in Combination With Rituximab or Obinutuzumab Plus CHOP in Patients With RIchter Syndrome

NCT0618664823 locations

Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation

NCT046790124 locations